hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06328621, orgStudyIdInfo id: 19594, secondaryIdInfos id: NCI-2021-05881, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 19594, type: OTHER, domain: City of Hope Medical Center, secondaryIdInfos id: P30CA033572, type: NIH, link: https://reporter.nih.gov/quickSearch/P30CA033572, briefTitle: Lung Cancer Risk Assessment and Etiology, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-07-02, primaryCompletionDateStruct date: 2029-06-15, completionDateStruct date: 2029-06-15, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: City of Hope Medical Center, class: OTHER, collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: This study examines the biological and social determinants that may increase the risk for lung cancer in patients and never-smoking individuals. Biological characteristics of a person can include their genetics and social determinants of a person can include their education, income, and environment, all of which can impact their health. Information collected in this study may help increase early detection of lung cancer., conditionsModule conditions: Lung Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Electronic Health Record Review, interventions name: Survey Administration, outcomesModule primaryOutcomes measure: Frequency of germline alterations, otherOutcomes measure: Frequency of abnormal radiographic findings, otherOutcomes measure: Associations between molecular phenotypes, social determinants of health, and the presence of lung cancer and related outcomes, otherOutcomes measure: Liquid biopsy (LB) test sensitivity, otherOutcomes measure: LB test specificity, otherOutcomes measure: LB test positive predictive value, otherOutcomes measure: LB test negative predictive value, otherOutcomes measure: LB test accuracy comparing LB genetic mutations to those found on next generation sequencing (NGS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: City of Hope Medical Center, status: RECRUITING, city: Duarte, state: California, zip: 91010, country: United States, contacts name: Stacy W. Gray, role: CONTACT, phone: 626-218-6639, email: stagray@coh.org, contacts name: Stacy W. Gray, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.13945, lon: -117.97729, hasResults: False
protocolSection identificationModule nctId: NCT06328595, orgStudyIdInfo id: Cross sectional, briefTitle: Muscular and Joint Symptoms in COVID-19 Patients: Insights From Syria, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-04-22, primaryCompletionDateStruct date: 2023-05-04, completionDateStruct date: 2023-08-20, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Syrian Private University, class: OTHER, descriptionModule briefSummary: Observation study, shows the relation between musckeloskeletal symptoms with during and post Covid-19 infection, by asking participants questions about there age,job,which vaccination covid participants took, residual area, social status, number of time of covid-19 infection, number of joint affected and duration of joint pain and asking if there any malaise or fatigue, conditionsModule conditions: Musculoskeletal Pain, conditions: COVID-19, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1039, type: ACTUAL, outcomesModule primaryOutcomes measure: The Demographic characteristics were classified into four groups: Gender, Residual area, education level., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 78 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mohamad Zaid Ahmad Abdalla, city: Damascus, country: Syrian Arab Republic, geoPoint lat: 33.5102, lon: 36.29128, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-09-24, uploadDate: 2024-03-22T04:16, filename: Prot_SAP_000.pdf, size: 235804, hasResults: False
protocolSection identificationModule nctId: NCT06328582, orgStudyIdInfo id: Zhenjiu Post-stroke dysphagia, briefTitle: Acupuncture Technique for Restoring Consciousness on Post-stroke Dysphagia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: This is a randomized controlled study, including post-stroke dysphagic patients. The participants were divided randomly into the experimental group and the control group. Both two groups were given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given Acupuncture Technique for Restoring Consciousness. Swallowing function will be compared before and after treatment., conditionsModule conditions: Dysphagia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Routine rehabilitation training, interventions name: Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture, outcomesModule primaryOutcomes measure: Penetration-Aspiration Scale, secondaryOutcomes measure: Functional Oral Intake Scale, secondaryOutcomes measure: Gugging Swallowing Screen, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328569, orgStudyIdInfo id: VR Wallenberg Syndrome, briefTitle: Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:the efficacy of Virtual Reality Therapy in the rehabilitation of patients with dysphagia in Wallenberg syndrome.Participants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy., conditionsModule conditions: Wallenberg Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Virtual Reality Therapy, interventions name: Conventional dysphagia treatment, outcomesModule primaryOutcomes measure: standardized swallowing assessment, secondaryOutcomes measure: Murray secretion scale, secondaryOutcomes measure: penetration-aspiration scale, secondaryOutcomes measure: swallowing-quality of life, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328556, orgStudyIdInfo id: Ultrasound-guided Botulinum, briefTitle: Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: Ultrasound-guided injection is a visual, convenient, and radiation-free technique that allows real-time observation of the needle insertion process and drug injection location. The combination with a balloon for fixation further enhances the precision of the injection. In this study, the investigators employed ultrasound-guided injection combined with balloon localization for cricopharyngeal muscle botulinum toxin injection treatment and conducted clinical observations., conditionsModule conditions: Cricopharyngeal Achalasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: botulinum toxin type A, interventions name: Injection, outcomesModule primaryOutcomes measure: functional oral intake scale, secondaryOutcomes measure: Penetration-Aspiration Scale, secondaryOutcomes measure: The Fiberoptic Endoscopic Dysphagia Severity Scale, secondaryOutcomes measure: Murray secretion scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328543, orgStudyIdInfo id: N-20210046 4th project, briefTitle: Itch Sensation Induced by Multiple Applications of Pruritogens (Temporal Summation), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Aalborg University, class: OTHER, descriptionModule briefSummary: In This experiment, the investigators would like to design a new itch model based on the temporal summation of pruritic stimuli. The hypothesis behind this study (temporal summation) is that two overlapped applications of pruritogens will result in a higher itch sensation compared with a single application., conditionsModule conditions: Histamine, conditions: Cowhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: The participants will randomly receive applications of cowhage and histamine, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Participant will be blinded about application of pruritogens, whoMasked: PARTICIPANT, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: Histamine, interventions name: Cowhage, outcomesModule primaryOutcomes measure: Assessment of itch, primaryOutcomes measure: Assessment of pain, secondaryOutcomes measure: Microvascular reactivity, secondaryOutcomes measure: Alloknesis, secondaryOutcomes measure: Mechanically evoked itch, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328530, orgStudyIdInfo id: N-20210046 3rd project, briefTitle: Itch Sensation Induced by Simultaneous Application of Pruritogens (Spatial Summation), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Aalborg University, class: OTHER, descriptionModule briefSummary: In This experiment, the investigators would like to design a new itch model based on the spatial summation of pruritic stimuli. The hypothesis behind this study (spatial summation) is that two simultaneous applications of pruritogens will result in higher itch sensation compared with a single application of pruritogen., conditionsModule conditions: Histamine, conditions: Cowhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: The participants will randomly receive applications of cowhage and histamine., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Participant will be blinded about application of pruritogens., whoMasked: PARTICIPANT, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Cowhage, interventions name: Histamine, outcomesModule primaryOutcomes measure: Assessment of itch, primaryOutcomes measure: Assessment of pain, secondaryOutcomes measure: Alloknesis, secondaryOutcomes measure: Mechanically evoked itch, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328504, orgStudyIdInfo id: Cashew Protocol, briefTitle: Efficacy of Cashew Nut Protein Immunotherapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-04-21, completionDateStruct date: 2027-04-21, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Medical University of Warsaw, class: OTHER, descriptionModule briefSummary: It is a randomized, sigle-center, controlled trial to evaluate the effectiveness of oral immunotherapy with cashew protein compared with standard treatment (elimination diet) in pediatric patients with cashew allergy., conditionsModule conditions: Food Allergy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ESTIMATED, armsInterventionsModule interventions name: Cashew immunotherapy, outcomesModule primaryOutcomes measure: Cashew full tolerance, secondaryOutcomes measure: Cashew partial tolerance, secondaryOutcomes measure: OIT safety, secondaryOutcomes measure: Wheal diamater in skin prick tests, secondaryOutcomes measure: SIgE and IgG 4 levels, secondaryOutcomes measure: BAT scores, secondaryOutcomes measure: Quality of life- FAQLQ, secondaryOutcomes measure: Air condensate, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Medical University of Warsaw, city: Warsaw, state: Mazowieckie, zip: 02-091, country: Poland, contacts name: Agnieszka Szczukocka-Zych, MD, role: CONTACT, phone: +48 22 3179427, email: agnieszka.szczukocka-zych@wum.edu.pl, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06328491, orgStudyIdInfo id: OZUHN-014, secondaryIdInfos id: 22-5325, type: OTHER, domain: University Health Network, briefTitle: Erdafitinib in Metastatic Steroid-cell Ovarian Cancer, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-30, primaryCompletionDateStruct date: 2022-08-22, completionDateStruct date: 2022-08-22, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: University Health Network, Toronto, class: OTHER, descriptionModule briefSummary: This is a single participant study of erdafitinib for the treatment of a patient with metastatic steroid-cell tumor of the ovary., conditionsModule conditions: Ovarian Cancer, conditions: Steroid Cell Tumor, Malignant, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1, type: ACTUAL, armsInterventionsModule interventions name: Erdafitinib, outcomesModule primaryOutcomes measure: Tumor response, primaryOutcomes measure: Overall health status, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Princess Margaret Cancer Centre, city: Toronto, state: Ontario, zip: M5G 2M9, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06328478, orgStudyIdInfo id: Predictors of AKI in PICU., briefTitle: Predictors of Acute Kidney Injury in Critically Ill Children Admitted to PICU., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Predictors of Acute Kidney Injury in critically ill children admitted to PICU during one year., conditionsModule conditions: Acute Kidney Injury, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Observational prospective study., outcomesModule primaryOutcomes measure: Incidence of acute kidney injury and survival to discharge from the PICU., eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328465, orgStudyIdInfo id: IEO 1108, briefTitle: fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases, acronym: fREEDOM, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-11-22, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI., conditionsModule conditions: Invasive Breast Cancer, conditions: HER2-positive Breast Cancer, conditions: Triple Negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 145, type: ESTIMATED, armsInterventionsModule interventions name: Diffusion whole body MRI, outcomesModule primaryOutcomes measure: 5-year overall survival, secondaryOutcomes measure: Overall survival of patients underwent local treatment, secondaryOutcomes measure: Breast cancer specific survival, secondaryOutcomes measure: Safety of local treatment, secondaryOutcomes measure: Anxiety assessment, secondaryOutcomes measure: Health state assessment, secondaryOutcomes measure: Ability to Cope With Trauma assessment, secondaryOutcomes measure: Personality assessment, secondaryOutcomes measure: Acceptability and perception of DWB-MRI, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, zip: 20141, country: Italy, contacts name: Monica Iorfida, MD, role: CONTACT, phone: +390257489970, email: monica.iorfida@ieo.it, contacts name: Mara Negri, role: CONTACT, phone: +390257489536, email: mara.negri@ieo.it, contacts name: Monica Iorfida, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06328452, orgStudyIdInfo id: MASLD, briefTitle: Risk Factors and Impact MASLD in Patients With IBD, acronym: MASLD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Inflammatory bowel disease (IBD) is a chronic disease characterized by remitting and relapsing inflammation of the gastrointestinal tract. Crohn's disease (CD) and ulcerative colitis (UC) are the two main types of IBD and their incidence and prevalence are increasing.In about 5-50% of patients with IBD, there are several extraintestinal manifestations as primary sclerosing cholangitis, autoimmune/granulomatous hepatitis, and non-alcoholic fatty liver disease (NAFLD).Metabolic dysfunction-associated steatotic liver disease "MASLD"(formerly NAFLD) is a spectrum of hepatic diseases associated with metabolic and cardiovascular disorders, such as obesity, insulin resistance (IR), hypertension, dyslipidemia, impaired glucose tolerance and type 2 diabetes mellitus.The risk factors of developing liver steatosis in patients with IBD remain undetermined. Some studies have supported traditional risk factors, such as type 2 Diabetes mellitus (T2DM), weight gain, or obesity, to contribute to MAFLD development in patients with IBD. Other studies have highlighted the involvement of disease activity, duration, drug-induced liver injury and small bowel surgeries in MAFLD progression.Limited data are available on the frequency and risk factors of MASLD in Egyptian patients with IBD, and no published Egyptian study has addressed the clinical utility of serum steatosis markers in MASLD prediction in IBD population. Moreover, the impact of MASLD on IBD course is unclear. Therefore, we will conduct our study to shed some light on this issue., conditionsModule conditions: Metabolic Dysfunction-associated Steatotic Liver Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: FibroScan, outcomesModule primaryOutcomes measure: Assess the prevalence and risk factors of metabolic dysfunction associated steatotic liver disease among patients attending inflammatory bowel disease outpatient clinic, primaryOutcomes measure: Effect of metabolic dysfunction associated steatotic liver disease on inflammatory bowel disease course, secondaryOutcomes measure: Performance of serum steatosis markers in prediction of steatosis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False